ぶどう膜炎(Uveitis):治療薬開発パイプライン動向(2015年上半期版)

◆英語タイトル:Uveitis - Pipeline Review, H1 2015
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC6260IDB
◆発行日:2015年3月11日
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆ページ数:159
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[ぶどう膜炎(Uveitis):治療薬開発パイプライン動向(2015年上半期版)]についてメールでお問い合わせはこちら
当調査レポートでは、世界におけるぶどう膜炎(Uveitis)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・ぶどう膜炎(Uveitis)の概要
・ぶどう膜炎(Uveitis)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・ぶどう膜炎(Uveitis)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・ぶどう膜炎(Uveitis)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・ぶどう膜炎(Uveitis)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
*** レポート概要(サマリー)***

Uveitis – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Uveitis – Pipeline Review, H1 2015’, provides an overview of the Uveitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Uveitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Uveitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Uveitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Uveitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Uveitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Uveitis Overview 11
Therapeutics Development 12
Pipeline Products for Uveitis – Overview 12
Pipeline Products for Uveitis – Comparative Analysis 13
Uveitis – Therapeutics under Development by Companies 14
Uveitis – Therapeutics under Investigation by Universities/Institutes 18
Uveitis – Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Uveitis – Products under Development by Companies 22
Uveitis – Products under Investigation by Universities/Institutes 26
Uveitis – Companies Involved in Therapeutics Development 27
AbbVie Inc. 27
Aciont Inc. 28
Apitope International NV 29
BBB Therapeutics B.V. 30
Can-Fite BioPharma Ltd. 31
Clearside BioMedical, Inc. 32
Effimune SAS 33
Eleven Biotherapeutics Inc. 34
Endocyte, Inc. 35
Enzo Biochem, Inc. 36
EyeGate Pharmaceuticals, Inc. 37
ForSight VISION4, Inc. 38
HanAll Biopharma Co., Ltd. 39
Icon Bioscience, Inc. 40
IMMD Inc. 41
Johnson & Johnson 42
Neuroptis Biotech 43
Novartis AG 44
Ocata Therapeutics, Inc. 45
OncoNOx ApS 46
Panoptes Pharma Ges.m.b.H. 47
Pfizer Inc. 48
pSivida Corp. 49
Regeneron Pharmaceuticals, Inc. 50
Santen Pharmaceutical Co., Ltd. 51
SynDevRx, Inc. 52
TxCell SA 53
Virogenomics, Inc. 54
XOMA Corporation 55
Uveitis – Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Target 57
Assessment by Mechanism of Action 59
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
2B3-201 – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
adalimumab – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ATXUV-1 – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ATXUV-2 – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
B27-PD – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
celecoxib – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
CF-101 – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Col-Treg – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Cytectin – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
dexamethasone acetate – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Dexamethasone Sodium Phosphate-Visulex – Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
EBI-028 – Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
EC-1496 – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
EC-1669 – Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
fluocinolone acetonide – Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
FR-104 – Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
gevokizumab – Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
HL-036 – Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
IBI-70090 – Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
IMD-0354 – Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
INV-17 – Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
LFG-316 – Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
lodamin – Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
NOP-3 – Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
NS-2 – Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
OX-1001 – Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
PA-2612 – Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Peptides to Modulate TCR for Uveitis – Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
plastoquinone decyl triphenylphosphonium bromide – Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
PP-001 – Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
PPL-003 – Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Recombinant Enzymes for Uveitis – Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
sarilumab – Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
sirolimus – Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Small Molecules to Inhibit Kinase for Uveitis and Inflammatory Bowel Disease – Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
Stem Cell Therapy for Autoimmune Diseases – Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
triamcinolone acetonide – Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
V-404 – Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
Uveitis – Recent Pipeline Updates 118
Uveitis – Dormant Projects 147
Uveitis – Discontinued Products 150
Uveitis – Product Development Milestones 151
Featured News & Press Releases 151
Jan 05, 2015: Clearside Biomedical Initiates Phase 2 Clinical Trial For the Treatment of Macular Edema Associated With Non-Infectious Uveitis 151
Dec 18, 2014: Aldeyra Therapeutics Submits FDA IND Filing for Noninfectious Anterior Uveitis 151
Dec 17, 2014: TxCell Receives EU Orphan Drug Designation For Col-Treg In The Treatment Of Non-Infectious Uveitis 152
Dec 16, 2014: Aldeyra Therapeutics Abstract Accepted at 2015 American Academy of Allergy Asthma & Immunology Annual Meeting 153
Dec 16, 2014: Portage announces further successful validation of its new proprietory cell permeable peptide platform technology 153
Oct 28, 2014: TxCell achieves positive results for Col-Treg in a model of autoimmune uveitis 154
Oct 15, 2014: Clearside Biomedical Announces Ongoing Results in Phase 1/2 Clinical Trial in Patients with Non-infectious Uveitis 155
Oct 06, 2014: Portage Announces Additional Consultants To Expedite Its PPL-003 Development Programs 155
May 22, 2014: Col-Treg granted Advanced Therapy Medicinal Product classification by the European Medicines Agency 156
May 20, 2014: AbbVie Receives Orphan Drug Designation for HUMIRA from the U.S. Food and Drug Administration for the Investigational Treatment of Certain Forms of Non-infectious Uveitis 157
Appendix 158
Methodology 158
Coverage 158
Secondary Research 158
Primary Research 158
Expert Panel Validation 158
Contact Us 158
Disclaimer 159

[List of Tables]
Number of Products under Development for Uveitis, H1 2015 12
Number of Products under Development for Uveitis - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 15
Number of Products under Development by Companies, H1 2015 (Contd..1) 16
Number of Products under Development by Companies, H1 2015 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2015 18
Comparative Analysis by Late Stage Development, H1 2015 19
Comparative Analysis by Clinical Stage Development, H1 2015 20
Comparative Analysis by Early Stage Development, H1 2015 21
Products under Development by Companies, H1 2015 22
Products under Development by Companies, H1 2015 (Contd..1) 23
Products under Development by Companies, H1 2015 (Contd..2) 24
Products under Development by Companies, H1 2015 (Contd..3) 25
Products under Investigation by Universities/Institutes, H1 2015 26
Uveitis - Pipeline by AbbVie Inc., H1 2015 27
Uveitis - Pipeline by Aciont Inc., H1 2015 28
Uveitis - Pipeline by Apitope International NV, H1 2015 29
Uveitis - Pipeline by BBB Therapeutics B.V., H1 2015 30
Uveitis - Pipeline by Can-Fite BioPharma Ltd., H1 2015 31
Uveitis - Pipeline by Clearside BioMedical, Inc., H1 2015 32
Uveitis - Pipeline by Effimune SAS, H1 2015 33
Uveitis - Pipeline by Eleven Biotherapeutics Inc., H1 2015 34
Uveitis - Pipeline by Endocyte, Inc., H1 2015 35
Uveitis - Pipeline by Enzo Biochem, Inc., H1 2015 36
Uveitis - Pipeline by EyeGate Pharmaceuticals, Inc., H1 2015 37
Uveitis - Pipeline by ForSight VISION4, Inc., H1 2015 38
Uveitis - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 39
Uveitis - Pipeline by Icon Bioscience, Inc., H1 2015 40
Uveitis - Pipeline by IMMD Inc., H1 2015 41
Uveitis - Pipeline by Johnson & Johnson, H1 2015 42
Uveitis - Pipeline by Neuroptis Biotech, H1 2015 43
Uveitis - Pipeline by Novartis AG, H1 2015 44
Uveitis - Pipeline by Ocata Therapeutics, Inc., H1 2015 45
Uveitis - Pipeline by OncoNOx ApS, H1 2015 46
Uveitis - Pipeline by Panoptes Pharma Ges.m.b.H., H1 2015 47
Uveitis - Pipeline by Pfizer Inc., H1 2015 48
Uveitis - Pipeline by pSivida Corp., H1 2015 49
Uveitis - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 50
Uveitis - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015 51
Uveitis - Pipeline by SynDevRx, Inc., H1 2015 52
Uveitis - Pipeline by TxCell SA, H1 2015 53
Uveitis - Pipeline by Virogenomics, Inc., H1 2015 54
Uveitis - Pipeline by XOMA Corporation, H1 2015 55
Assessment by Monotherapy Products, H1 2015 56
Number of Products by Stage and Target, H1 2015 58
Number of Products by Stage and Mechanism of Action, H1 2015 60
Number of Products by Stage and Route of Administration, H1 2015 62
Number of Products by Stage and Molecule Type, H1 2015 64
Uveitis Therapeutics - Recent Pipeline Updates, H1 2015 118
Uveitis - Dormant Projects, H1 2015 147
Uveitis - Dormant Projects (Contd..1), H1 2015 148
Uveitis - Dormant Projects (Contd..2), H1 2015 149
Uveitis - Discontinued Products, H1 2015 150

[List of Figures]
Number of Products under Development for Uveitis, H1 2015 12
Number of Products under Development for Uveitis - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 14
Number of Products under Investigation by Universities/Institutes, H1 2015 18
Comparative Analysis by Clinical Stage Development, H1 2015 20
Comparative Analysis by Early Stage Products, H1 2015 21
Assessment by Monotherapy Products, H1 2015 56
Number of Products by Top 10 Targets, H1 2015 57
Number of Products by Stage and Top 10 Targets, H1 2015 57
Number of Products by Top 10 Mechanism of Actions, H1 2015 59
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 59
Number of Products by Top 10 Routes of Administration, H1 2015 61
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 62
Number of Products by Top 10 Molecule Types, H1 2015 63
Number of Products by Stage and Top 10 Molecule Types, H1 2015 64

*** 掲載企業 ***

AbbVie Inc.
Aciont Inc.
Apitope International NV
BBB Therapeutics B.V.
Can-Fite BioPharma Ltd.
Clearside BioMedical, Inc.
Effimune SAS
Eleven Biotherapeutics Inc.
Endocyte, Inc.
Enzo Biochem, Inc.
EyeGate Pharmaceuticals, Inc.
ForSight VISION4, Inc.
HanAll Biopharma Co., Ltd.
Icon Bioscience, Inc.
IMMD Inc.
Johnson & Johnson
Neuroptis Biotech
Novartis AG
Ocata Therapeutics, Inc.
OncoNOx ApS
Panoptes Pharma Ges.m.b.H.
Pfizer Inc.
pSivida Corp.
Regeneron Pharmaceuticals, Inc.
Santen Pharmaceutical Co., Ltd.
SynDevRx, Inc.
TxCell SA
Virogenomics, Inc.
XOMA Corporation

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※H&Iグローバルリサーチは調査サービスを通じて、お客様の海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをご提供しております。
※当市場調査資料"ぶどう膜炎(Uveitis):治療薬開発パイプライン動向(2015年上半期版)"は"Global Markets Direct社"が調査・発行しており、H&Iグローバルリサーチが販売します。お気軽にお問い合わせください。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。